4th International Symposium on New Quinolones

Proceedings of the 4th International Symposium on New Quinolones held at Munich, Germany, August 27-29, 1992

Organising Committee
E. Rubinstein (Chairman)
D. Adam
C. Carbon
R. Moellering
F. Waldvogel

Technical Editor
Harriet M. Bryson

This supplement is a cooperative publishing venture of Adis International Limited and the 4th ISNQ Organizing Committee

Copyright: © 1993 Adis International Limited. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means electronic or mechanical including photocopying or recording or by any information storage and retrieval system without permission in writing from the publisher. Although great care has been taken in compiling and checking the information given in this publication to ensure that it is accurate the authors the publisher and their servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors omissions or inaccuracies in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

The appearance of the code at the head of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for the personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center Inc., 21 Congress Street, Salem, Massachusetts 01970, USA, for copying beyond that permitted by sections 107 or 108 of the US Copyright Law. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

Drugs is indexed in Current Contents, Index Medicus and Excerpta Medica.

Publisher's Note: The opinions expressed in this publication are those of the individual authors, and are not attributable to the publisher, editor or editorial board of Drugs.
List of Contributors

Foreword
E. Rubinstein

STATE-OF-THE-ART PRESENTATIONS

1-7
The Future of the Quinolones
Andriole VT

8-14
Quinolone Mode of Action – New Aspects
Hooper DC

15-23
Mechanisms of Resistance to Quinolones
Cambau E, Gutmann L

24-28
The Epidemiology of Bacterial Resistance to Quinolones
Acar JF, O'Brien TF, Goldstein FW, Jones RN

29-36
Quinolones in Intracellular Infections
Pechère J-C

37-41
Use of the Quinolones in Paediatrics
Schaad UB

42-45
The Use of Quinolones in Developing Countries
Rodriguez-Noriega E, Morfin-Otero R, Esparza-Ahumada S

46-53
Postmarketing Surveillance of Quinolones, 1990 to 1992
Davey P, McDonald T

54-58
Synergy and Antagonism of Fluoroquinolones with Other Classes of Antimicrobial Agents
Neu HC

59-64
Safety and Tolerability of Fluoroquinolones
Norby SR, Lietman PS

65-72
Fluoroquinolones: Interaction Profile during Enteral Absorption
Deppermann K-M, Lode H

73-80
Use of the Quinolones for the Prophylaxis and Therapy of Infections in Immunocompromised Hosts
Maschmeyer G

81-90
Use of the Quinolones in the Prophylaxis and Treatment of Granulocytopenic Immunocompromised Cancer Patients
Van der Auwera P, Gérain J

91-97
Quinolones in the Treatment of Lower Respiratory Tract Infections in Adult Patients
Carbon C
98-101 Fluoroquinolones in the Treatment of Cystic Fibrosis
Hoiby N, Pedersen SS, Jensen T, Valerius NH, Koch C

102-113 Fluoroquinolones and Surgical Prophylaxis
Dellamonica P, Bernard E

114-118 Quinolones in the Treatment of Acute Bacterial Diarrhoeal Diseases
Akalin HE

119-124 Quinolones in Salmonella typhi Infection
DuPont HL

125-133 Impact of the Fluoroquinolones on Gastrointestinal Flora
Korten V, Murray BE

134-138 Quinolones in Sexually Transmitted Diseases
Ridgway GL

139-144 Management of Lower Urinary Tract Infections
Bailey RR

POSTER PRESENTATIONS

Mechanism of Action

145-147 Hydrophobicity of 11 Fluoroquinolones and Antibacterial Activity, Activity against DNA Gyrase and Uptake
Bazile S, Moreau NJ, Bouzard D, Essiz M

148-149 Affinity of Sparfloxacin and 4 Other Fluoroquinolones for Magnesium and Effect on Antibacterial Activity
Lecomte S, Coupry C, Chenon MT, Moreau NJ

150-151 Effect of Cations and EDTA upon the Activity of 18 Quinolones, Gentamicin, Ceftazidime and Polymixin against Gram-Negative and Gram-Positive Bacteria
Marshall AJH, Piddock LJV

Epidemiological Surveillance and Quinolones Resistance

152-156 Sensitivity of Community- and Hospital-Acquired Bacterial Isolates to Sparfloxacin in Comparison with Other Antibiotics
Focht J, Nösner K, Kresken M

157-158 Antimicrobial Activities of Ciprofloxacin and 6 Other New Quinolones
In Vitro against Recent Clinical Pathogens
Nakashio S, Hori S, Shimada J

159-160 Comparative In Vitro Activity of Ofloxacin and Other Antimicrobial Agents Used in Oral Therapy in General Practice
Focht J, Kraus H, Nösner K
161-162 6 Years of Experience with Sensitivity Testing of Various Gram-Negative and Gram-Positive Clinical Strains to Ofloxacin
Zaremba M, Rozkiewicz M, Pydzińska J, Domańska T, Borowski J

163-164 MIC Audit of Routine Ciprofloxacin Sensitivity Testing

165-166 Annual Changes in the Susceptibility of Clinical Isolates to Ofloxacin
Takubo T

167-169 The North American Component (USA, Canada) of an International Comparative MIC Trial Monitoring Ofloxacin Resistance
Hoban D, Jones RN

170-171 Surveillance of Bacterial Resistance to Quinolones
Wang Fu, Zhu De-Mei, Wang Yu-qing

172-173 Clinical and Experimental Study of the Appearance of Norfloxacin-Resistant P. aeruginosa in UTI
Onodera S, Kiyota H, Goto H, Machida T, Iyobe S

174-175 Prevalence of Ciprofloxacin Resistance in Multiresistant Gram-Negative Intensive Care Unit Isolates
Khurana CM, Wojack BR

176 High Level Quinolone Resistance among Escherichia coli Clinical Isolates
Alarcbn T, Pita J, Piddock LJ, López-Brea M

177-178 Emergence of Resistance of Uropathogens to Quinolones
Naber KG, Witte W, Bauernfeind A, Wiedemann B

179 Resistance to Quinolones and Other Antibiotics Assessed by Factor Analysis
Leibovici L, Wysenbeek AJ, Konisberger H, Samra Z, Pitlik SD, Drucker M

New Quinolones

180 In Vitro and In Vivo Antibacterial Activity of E-4868
Xicota MA, Coll R, Esteve M, Pares M, Guinea J

181 In Vitro Activities of AM-1155 against Chlamydia spp. and M. avium Complex

182-183 In Vitro Antibacterial Activity of AM-1155
Hirai K, Yasue T, Hosaka M, Wakabayashi E, Tomizawa H, Nishino K

184-186 Comparative In Vitro Activity of AM-1155, a New Quinolone, against Anaerobic Bacteria

187 In Vitro Activity of PD 131628 against Anaerobic Bacteria
Nord CE, Hagelbäck A
188-189 Comparative *In Vitro* Activity of PD 131628, the Microbiologically Active Constituent of the Prodrug CI-990 (PD 131112)
*Felmingham D, Robbins MJ, Ghosh G, Mehta M, Leakey A, Clark S, Mumtaz G, Ridgway GL, Gruneberg RN*

190-191 *In Vitro* Activity of PD 131628 and Effects on Virulence and OMPs
*Cipriani P, Giordano A, Magni A, Trancassini M, Filadoro F*

192-193 Comparative *In Vitro* Antibacterial Activity of PD 131628, the Active Metabolite of CI-990
*Callanan JJ, Roditi DOJ, Forder AA*

**Activity of Quinolones against *Streptococcus pneumoniae***

194-195 Susceptibility of 170 Penicillin-Susceptible and -Resistant Pneumococci to Various Antimicrobials
*Spangler SK, Jacobs MR, Appelbaum PC*

196-197 Activity of Quinolone Antibacterials against *Streptococcus pneumoniae*
*Morrissey I, Smith JT*

198 Induction of Resistance of *Streptococcus pneumoniae* to Levofloxacin, Ciprofloxacin and Norfloxacin *In Vitro*
*Fu KP, Lafredo SC, Folenbo BD*

**Activity of Quinolones against Staphylococci***

199-200 Comparative *In Vitro* Activity of Sparfloxacin against Gram-Positive Cocci
*Kocagöz S, Gür D, Uzun Ö, Özkuyumcu C, Akova M, Akalin HE*

201 Increased Incidence of Gram-Positive Pathogens Subsequent to Quinolone Therapy in UTI
*Taufer M, Mailer H, Pummer K, Wandschnieder G*

202 Resistance Mechanism of MRSA to Quinolones
*Zhang Yong-xin, Zhu De-mei, Wang F, Tanaka M, Sato K, Osada Y*

203 Clonal Dissemination of QR-MRSA Resulting from Inappropriate Hospital Hygiene and Prophylaxis
*Witte W, Henck D*

204-205 *In Vitro* Activity of 5 Quinolones, Cotrimoxazole, Imipenem, and Rifampicin against Recent Isolates of *S. aureus*
*Husain N, Manzor O, Markowitz N, Saravolatz L*

206-207 Advantages Offered by Sparfloxacin against Clinically Isolated *Staphylococcus aureus* Resistant to Fluoroquinolones
*Tetreau C, Moreau N*

208-209 *In Vitro* Activity of Fluoroquinolones, Fusidic Acid and Rifampicin Against Nongrowing Staphylococci
*Carsenti-Etesse H, Bernard E, Pradier C, Durant J, Bensoussan M, Dellamonica P*
210 In Vitro Antibacterial Activity of Levofloxacin against MRSA
Yamaji E, Akieda Y, Watanabe T, Suzuki T, Itokawa K, Tanaka T, Nakayama I

211-212 In Vitro Antibacterial Activity of AM-1155 against MRSA
Nakayama I, Akieda Y, Watanabe T, Suzuki T, Itokawa K, Yamaji E

213-214 Influence of Exogenous Factors and Antibiotics on the Cytoplasmic Membrane Proteins in S. aureus
Cullmann W, Schlunegger H

Quinolone Activity against Intracellular Pathogens Including Mycobacteria

215-216 In Vitro and In Vivo Activity of AM-1155 against Mycoplasma pneumonias

217-218 Bactericidal Activity of Ofloxacin, Levofloxacin and Other Fluoroquinolones Compared with Agents Proven against Listeria monocytogenes
Cherubin CE, Stratton CW

219-220 Activity of Sparfloxacin and Other Quinolones against Mycobacteria
Martin-Luengo F, Sempere MA

221-222 Antileprosy Action of Ofloxacin in Combination with Rifampicin or DDS, and Benzoxazinorifamycin in Mice, and their In Vitro Activities against Leprosy Bacilli
Tomioka H, Saito H, Sato K, Hidaka T

223-224 Ofloxacin-Based Chemotherapy in Multiply Drug-Resistant Pulmonary Tuberculosis
Willcox PA, Groenewald PJ, Mackenzie CR

225-226 Clinical Trial of Sparfloxacin in the Treatment of Leprosy
Franzblau SG, Chan GP

227-228 Failure of Quinolones Alone and in Combination To Cure Experimental Murine Brucellosis
Lang R, Shasha B, Kolman S, Rubinstein E

In Vitro Laboratory Studies

229-231 Activity of Ciprofloxacin against Respiratory Pathogens Capable of Producing β-Lactamase
Speciale A, Caccamo F, Di Marco R, Blandino G, Nicoletti G

232-233 Sensitivity of Ciprofloxacin-Resistant Isolates of Acinetobacter and Xanthomonas to 4 New Quinolones
Roberts AP, Talboys CA, Azadian BS

234-235 In Vitro Effect of Ofloxacin Alone and in Combination with Ceftazidime or Gentamicin against P. aeruginosa
Smith KR, Pate MS, Cobbs CG, Saag MS
Bactericidal Activity of Fluoroquinolones against Enterobacteria Isolated from Nosocomial Respiratory Tract Infections
Allouch PY, Decuyper C, Pangon BH, Ballereau M, Ghnassia JC

The Effect of Ofloxacin on Production of Exoenzymes by Pseudomonas aeruginosa
Mizukane R, Kaku M, Ishida K, Koga H, Kohno S, Hara K

Release of Newer Quinolones from Acrylic Bone Cement and Fibrin Clots In Vitro
Kanellakopoulou K, Tsourvakas S, Hatzigrigoris P, Chryssouli Z, Dounis E, Giamarellou H

Pharmacodynamics

Pharmacokinetic-Bactericidal Correlations after a Single 200mg IV Dose of Ciprofloxacin
Dan M, Poch F, Quassem C, Kitzes R

Comparative Pharmacokinetics and Serum Bactericidal Activities (SBA) of Ciprofloxacin (C) and Ofloxacin (O) Following Single Dose (Oral [PO] and Intravenous [IV]) Administration
Weinstein MP, Echols RM, Kowalsky SF, Meller AH

Bacterial Killing and Reduction in Bacterial Virulence Contribute to the Efficacy of Quinolones
Sonstein SA, Sweeney MT

A Pharmacokinetic Method of Assessing Antibiotics Exhibiting an Appreciable Postantibiotic Effect
Lubowski TJ, Nightingale CH, Sweeney K, Quintiliani R

Dosage and Administration of Ofloxacin in Patients with Chronic RTI
Tsubura E, Masuno T, Fujimura N

Pharmacokinetics: Penetration into Body Tissues and Fluids

Tissue Distribution Pharmacokinetics of Ciprofloxacin vs Ofloxacin in Rabbits
Colino CI, Sanchez Navarro A, Lanao JM, Dominguez-Gil A

Profile of Ciprofloxacin in Serum and in Pleural Exudate after IV Bolus Injection in Rats
Miglioli PA, Ghiotto E, Gaion RM

Absorption and Secretion of Sparfloxacin in the Isolated Rabbit Intestinal Tract
Huneau J-F, Tome D, Ramon J, Carbon C, Rubinstein E

Elimination of Lomefloxacin in Rat Intestinal Loop
Vergin H, Metz R, Nau R, Kinzig M, Sorgel F
253-254 Single Dose Oral Ciprofloxacin for Perioperative Antibiotic Prophylaxis in Lung Surgery
Rohwedder R, Della Torre H, Schlecker H

255-256 Perioperative Prophylaxis with Ofloxacin in Vascular Surgery: Antibiotic Concentrations in Serum, Lymph Nodes and Vessel Wall
Oldorf P, Wendling P

257-258 Penetration of Ofloxacin into Heart Valves, Myocardium, Mediastinal Fat and Sternal Bone Marrow in Man

259 Penetration of Levofloxacin into Bronchoalveolar Lavage Fluid
Nagai H, Yamasaki T, Masuda M, Goto Y, Tasiro T, Nasu M

260-261 Excretion of Levofloxacin into Bile and Gallbladder Tissue

262 Administration of Ofloxacin before Quasi-Aseptic Surgery
Yagyu T, Kawabata A, Kawakita M, Shimizu R, Suzuki T

263-264 Monitoring Blood Concentrations of Ofloxacin by Use of Saliva
Shiba K, Yoshida M, Saito A, Sakai O

470 Comparison of Blister Fluid Penetration of Fleroxacin and its Metabolites between Young and Elderly
LeBel M, Kinzig M, Sorgel F

Pharmacokinetics in Disease States

265 Clinical Evaluation of Ofloxacin at a Daily Dosage Adapted to Creatinine Clearance in Elderly Subjects
Veysseyer P, Martin F, Gallinari C, Moulias R, Chauvin M, Delval C

266 Accumulation of New Quinolones in the Blood of Elderly Patients
Morita M, Hasuda A, Nakagawa H, Suzuki K

267-268 Pharmacokinetics of Ofloxacin in Patients with Acute Renal Failure Undergoing Haemofiltration

269 Lomefloxacin Pharmacokinetics after Intravenous and Oral Administration in Patients with Acute Pyelonephritis
Robson RA, Bailey RR, Lynn KL

270 Evaluation of Ciprofloxacin and Ofloxacin Pharmacokinetics in Liver Cirrhosis
Miglioli PA, Palatini P, Orlando R, Sawadogo A

271-272 Comparative Pharmacokinetics of Oral and Intravenous Ciprofloxacin
Lettieri JT, Kaiser L, Krogl, Heller AH
Pharmacokinetics of Ciprofloxacin after Single Oral and Intravenous Doses
Lettieri JT, Rogge M, Echols R, Kaiser L, Heller AH

Concentrations of Ofloxacin in Bile and Serum of Patients with Biliary Tract Diseases and an Indwelling Nasobiliary Tube
Buttmann A, Kohler B, Schlauch D, Riemann JF, Kinzig M, Sörgel F

Quinolone Toxicity and Immunological Interactions

In Vivo Effect of Rufloxacin and Ciprofloxacin on T-Cell Subsets and Tumour Necrosis Factor Production
Gollapudi S, Chuah S-K, Thadepalli H, Harvey T, Thadepalli H

Quinolones and Induction of umuC and Mutagenicity
Power EGM, Phillips I

Preservation of Chemiluminescence of Human Leucocytes Subjected to Hyperosmolality by Ofloxacin and DR-3355

Lomefloxacin-Induced Photosensitivity Reaction
Tozawa K, Washida H

Binding Capacity of Quinolones to Cartilage Components
Forster C, Baumann-Wilschke I, Stahlmann R

Lack of Influence of Ciprofloxacin on the Effectiveness of Oral Contraceptives
Droppert RM, Scholten PC, Zwinkels M, Hoepelman IM, Te Velde ER

Hepatic Tolerance of Fluoroquinolone Combined with Rifampicin in Osteoarticular Infections
Halimi R, Cremieux AC, Alnot JY, Carbon C

Clinical and Haematological Safety of Long Term Quinolone Treatment
Lelekis M, Gargalianos P, Thanos A, Kosmidis J

Comparative Neurotoxicity Study of Ciprofloxacin and Sparfloxacn after Coadministration with Fenbufen in Rats
Iwamoto K, Naora K, Katagiri Y, Ichikawa N, Hayashibara M, Tanaka K, Yamaguchi T, Sekine Y

Synaptic Transmission in the Hippocampal Slice in the Presence of Aminophylline Alone and in Combination with Quinolones
Dimpfel W, Dalhoff A, Hofmann W, Schlüter G

Drug Interactions and Metabolism

Interactions of Different Drugs with the N-Demethylation of Pefloxacin in the Rat as Determined by Analysis of 14CO2-Exhalation
Does a Nonsteroidal Anti-Inflammatory Drug Modify the Pharmacokinetics of Pefloxacin and Ofloxacin?  Fillastre JP, Leroy A, Borsa-Lebas F, Etienne I, Gy C, Humbert G

Influence of the Zn-Antiulcer Agent on Ciprofloxacin Absorption in Beagle Dogs  Palka E, Vodopivec P

Influence of Cimetidine on Fleroxacin Pharmacokinetics  Portmann R

Influence of Antacids and Ranitidine on the Absorption of Levofloxacin in Men  Shiba K, Okazaki O, Aoki H, Shimada J, Sakai O

Pharmacokinetic Interaction of Temafloxacin with Cimetidine in Healthy Volunteers  Sawae Y

A Metabolite of Sparfloxacin in Urine: Properties and Quantification  Borner K, Borner E, Lode H

Quinolone Use in Immunocompromised Patients

Comparison of Efficacy and Safety of Treatment with Ofloxacin-Piperacillin and Amikacin-Piperacillin in Immunodepressed Febrile Neutropenic Patients  Harousseau JL, Lamagnere JP, Boasson M, Guyotat D, Moreau P, Linassier C, Levy S

Empirical Treatment of Pyrexial Neutropenic Cancer Patients with Pefloxacin or Ceftazidime  Papachristodoulou A, Alexopoulos CG, Vaslamatzis M

Effect of Tosufloxacin Tosilate in the Prevention of Secondary Infections in Patients with Haematological Malignancies  Sawada H, Tashima M, Yumoto Y, Okuda T, Tohi T, Okuma M


Quinolones in the Treatment of Community-Acquired Pneumonia in Neutropenic Patients  Krémery Jr V, Špánik S, Mardiak J, Fuchsberger P, Danišovcová A

Eye and ENT Infections

Intraocular Diffusion of IV Ofloxacin in Patients and Rabbits  Mounier M, Chauvin M, Denis F, Adenis JP, Ploy MC, Maes S
314-315  
The Influence of Acetazolamide on Ciprofloxacin and Pefloxacin Pharmacokinetics in Human Aqueous Humour  
Giamarellou H, Kanellas D, Kavouklis E, Dimakis K, Gabriel L

316-317  
Therapeutic Efficacy of Ciprofloxacin in Pseudomonal Ocular Infections in a Murine Model  
Zehavi-Willner T, Barnea A, Levy Y

318-319  
Clinical Study of Sparfloxacin in Ophthalmology  
Ooishi M and the Japanese Collaborative Study Group of Sparfloxacin in Ophthalmology

320-321  
Oral Pefloxacin and Ofloxacin in the Treatment of Malignant External Otitis  
Galanakis N, Giamarellou H, Christidis C, Dokianakis G, Sfikakis P

322-323  
Penetration and Concentration of Ofloxacin in Nose and Ear Tissues  
Tolsdorff P

324  
Oral Ciprofloxacin vs Cefuroxime Axetil in Acute Bacterial Sinusitis: A Pilot Study in Adults  
Klein GL, Heyd A, Echols R

325-326  
Ciprofloxacin in the Treatment of Suppurative Otitis Media and Sinusitis  
Miyamoto N, Kobayashi T, Baba S

327-328  
Efficacy of 2 Regimens of Local Ciprofloxacin in the Treatment of Ear Infections  
Garcia-Rodriguez JA, del Cañizo A, Garcia Sanchez JE, Garcia Garcia MI, de Miguel Martinez I, Muñoz Bellido JL, Garcia Sanchez E, Ramos A

329-330  
Clinical Studies of Sparfloxacin in the Field of Otorhinolaryngology  
Baba S and the Japanese Collaborative Study Group of Sparfloxacin in Otorhinolaryngology

331  
Clinical Studies of Sparfloxacin in Odontogenic Infections  
Sasaki J and the Japanese Collaborative Study Group of Sparfloxacin in Oral Surgery

Urinary Tract Infections

332  
Activity of Pefloxacin after 2 Years’ Single Dose Therapy for UTI  

333-334  
Randomised Comparison of Oral Ciprofloxacin vs Standard Parenteral Therapy in the Treatment of Complicated Urinary Tract Infections  

335-336  
Comparative Investigation of Ofloxacin 200mg Once Daily and 100mg Twice Daily in Patients with Complicated Urinary Tract Infections  
Ostri P, Holm-Nielsen A, Norregård P

337-338  
Efficacy and Safety of Single Dose Oral Pefloxacin in Acute Uncomplicated Lower UTI  
Scholz: H-R, Prieur B-L and the Pefloxacin Study Group
Sparfloxacin in the Treatment of Genitourinary Tract Infections
Kawada Y and the Japanese Collaborative Study Group of Sparfloxacin in Urology

Suppression of Recurrence of Complicated UTI by Low Dose Ciprofloxacin
Kumazawa J, Matsumoto T, Tanaka M, Takahashi K

Lomefloxacin versus Ciprofloxacin in the Treatment of Complicated or Recurrent UTI
Savitskaya KI, Trapeznikova MF, Nasonov VN, Datov VV, Kalinin VN, Nehorocheva AG, Solodilova OE, Schanin AG, Rusanova EV

Lomefloxacin Compared with Norfloxacin for the Treatment of Urinary Tract Infections in Spinal Injury Patients
Tosolini FA, Brown DJ

Comparison of Lomefloxacin and Cotrimoxazole in the Treatment of Complicated Urinary Tract Infections

Combined Intravenous and Oral Treatment in Complicated UTI: Lomefloxacin vs Ciprofloxacin
Michaelis WE and the Lomefloxacin Study Group

Prevalence and Treatment of Asymptomatic Bacteriuria in the Elderly
Del Rio G, Mestre J, Dalet F

A Comparative Study with Ciprofloxacin in Patients with Acute Epididymo-Orchitis
Reif S, Bornman MS, Mutambirwa S

Prostatitis

Sparfloxacin, Temafloxacin, Difloxacin, and Ciprofloxacin in the Treatment of Acute Prostatitis: An Experimental Model in Rats
Gasser TC, Drescher P, Madsen PO

Ofloxacin in Prostatitis
Aagaard J

Pefloxacin vs Ceftriaxone for Antimicrobial Prophylaxis in Endoscopic Urological Surgery
Jiménez-Cruz JF, Broseta E

Ofloxacin Prophylaxis in Infection after TURP
Toma H, Goya N, Itoh F, Yanagisawa H, Tomoe H, Kihara T, Okumura T

Concentration of Ofloxacin in Prostatic Tissue during TURP
Riedasch G, Mohring K, Brkovic D

Serum and Prostate Tissue Concentrations of Ofloxacin following Prophylactic Use in Transurethral Resection of the Prostate
Vahlensieck Jr W, Keller HJ, Groh R, Dinkeldein U
358-359 Analyses of Perioperative Ofloxacin Concentrations in Serum and Prostate Tissue
  Heinert G, Tan Th, Thielen H, Kräger J, Würth G, Essers L

360-361 Study of Ofloxacin in Comparison with Ceftriaxone as Antibiotic Prophylaxis for Sterile Urine Transurethral Resection of the Prostate
  Butreau M, Botto H, Delval C, Levy S

362-363 Temafloxacin in the Treatment of Chronic Bacterial Prostatitis

364-367 Treatment of Chronic Bacterial Prostatitis with Tosufloxacin
  Ikeuchi T, Kawamura N, Suzuki K, Onodera S and the Study Group on Chronic Bacterial Prostatitis in Japan

368-369 Levofloxacin in the Treatment of Chronic Prostatitis
  Suzuki K, Horiba M, Tanaka T, Naide Y, Yonetsu M

STD - Males

370 *In Vitro* and *In Vivo* Activities of Sparfloxacin against Chlamydial Species
  Kimura M, Kishimoto T, Hashiguchi K, Niki Y, Soejima R

371 Clinical Experience of Ofloxacin in the Treatment of Nongonococcal Urethritis
  Chen M-T, Chang C-P, Lu C-C, Huang WJS, Chang LS

372-373 Clinical Evaluation of Ofloxacin in Male Urethritis in Hong Kong
  Lo KK, Lai CF, Tang KC, Ng PS, Kam KM

374 Antimicrobial Activity of Ofloxacin against *Neisseria gonorrhoeae* and *Chlamydia trachomatis*: Clinical Experience in Japan
  Saito I, Saiko Y, Yokozawa M, Ono K

375-376 Multicentre Study of Ofloxacin in Male Urethritis in 7 Asian Countries
  Kawada Y

377-378 Ofloxacin in the Treatment of Urethritis in Men
  Choi SK, Lee MS, Han SW, Han SS, Le HS

379 Acute Nongonococcal Epididymitis: Aetiology and Levofloxacin Therapy
  Saito I, Suzuki A, Saiko Y, Yokozawa M, Ono K

Obstetrics and Gynaecology

380-381 Response of Vaginal Flora to Treatment of Cystitis with Enoxacin or Amoxicillin
  Petersen ME

382-383 Antimicrobial Activity and Pharmacokinetics of Sparfloxacin in Obstetrics and Gynaecology
  Cho N, Fukunaga K, Kanii K
Clinical Experience with Sparfloxacin in the Treatment of Gynaecological Infection
Matsuda S and the Japanese Collaborative Study Group of Sparfloxacin in Gynaecology

Basic and Clinical Studies of Levofloxacin in Obstetrics and Gynaecology
Yamada Y, Mikamo H, Izumi K, Ito K, Tamaya T

Skin and Soft Tissue Infections

Sparfloxacin in the Treatment of Skin and Soft Tissue Infections
Takahashi H and the Japanese Collaborative Study Group of Sparfloxacin in Dermatology

Lomefloxacin vs Ciprofloxacin in the Treatment of Non-Necrotising Skin and Skin Structure Infections
McCarty J

Clinical Trials of a New Quinolone, Sparfloxacin, in Skin and Skin Structure Infections
Watanabe T, Akieda Y, Suzuki T, Itokawa K, Yamaji E, Nakayama I

Lomefloxacin vs Ciprofloxacin in the Treatment of Non-Necrotising Skin and Skin Structure Infections
Monroe A

Intestinal Infections

In Vitro Activity of Quinolones against Clinical Isolates of Salmonella typhi Resistant to Chloramphenicol, Ampicillin and Cotrimoxazole
Barriga Angulo G, Alarcbn Olivares N, Castillo Torres NP

Multicentre Clinical Studies of Sparfloxacin in the Treatment of Infectious Enteritis
Imagawa Y and the Japanese Collaborative Study Group of Sparfloxacin on Infectious Enteritis

Efficacy and Safety of Pefloxacin in the Treatment of Typhoid Fever
Waiz A, Siddiqui M, Hossain M, Chakraborty B

Ofloxacin Therapy of Salmonella spp. and Pseudomonas pseudomallei Infections (Melioidosis) in Patients with HIV Antibodies
Tanphaichitra D, Srimuang S

Respiratory Tract Infections – Bronchitis

Clinical Study of Long Term Ciprofloxacin Therapy in Diffuse Panbronchiolitis

Ofloxacin and Erythromycin in the Management of Diffuse Panbronchiolitis
Sato A, Kayakawa H, Suda T
Contents

401-402 Ofloxacin and Macrolides in the Treatment of Diffuse Panbronchiolitis
Tanabe O, Komatuzaki K, Tada H, Shimizu A, Mochizuki T, Tanimoto H

403-404 Ciprofloxacin in the Treatment of Exacerbations of Chronic Respiratory Tract Infections
Odagiri S, Takigami T, Fukaya K

405-406 Clinical Response to Sparfloxacin in Respiratory Tract Infections
Soejima R, Hara K and a Japanese Collaborative Study Group

407-409 Ciprofloxacin in the Treatment of Lower Respiratory Tract Infections
Mazzei JA, Vujacich P, Fernández A, Tanco J

410 Ofloxacin and Erythromycin in Acute Exacerbations of Chronic Bronchitis
Egede F, Nielsen PB, Husfeldt P

411-412 Lomefloxacin vs Amoxicillin in Patients with Acute Exacerbations of Chronic Bronchitis: A UK Multicentre Study
Hamilton BA, O'Bryan-Tear CG, Markanday S

413 Lomefloxacin vs Ciprofloxacin in Lower Respiratory Infection
Nonikov VE, Makarova OV, Zubkov MN, Gugutzidze EN

414-415 Rufloxacin vs Amoxicillin in the Treatment of Acute Exacerbations of Chronic Bronchitis
Klietmann W, Focht J, Cesana M

416-417 Ofloxacin vs Cefuroxime in the Treatment of Lower Respiratory Infections in Moderately Immunocompromised Patients
Lam WK, Chau PY, Chan JCK, Ip MSM

418 Comparison of Ofloxacin and Cefaclor in the Treatment of Lower Respiratory Tract Infections in Adults
Dark DS, Farber M, Rice K

Respiratory Tract Infections – Pneumonias

419-420 Ofloxacin Combined with Amoxicillin/Clavulanic Acid for Empirical Treatment of Severe Community-Acquired Pneumonia
Le Chevalier B, Gallet E, Charbonneau P, Bazin C, Levy S, Delval C

421-422 Ofloxacin vs Erythromycin in Community-Acquired Pneumonia in General Practice
Nielsen PB, Husfeldt P, Egede F

423-424 Efficacy and Safety of Ofloxacin plus Piperacillin in the Treatment of Aspiration Pneumonia
Neviere R, Herengt F, Mathieu D, Wattel F

425-426 Oral Ciprofloxacin vs Intravenous Cefotaxime in the Treatment of Pneumonias in AIDS Patients
Efficacy and Safety of Ofloxacin IV in Ventilated Patients with COPD and Exacerbation of Pneumonia
Zielmann S, Grote R, Sydow M, Schmidt J, Banchardi H

Ciprofloxacin Eradicates Respiratory Tract Bacteria More Rapidly than Cephalosporins in Patients with Nosocomial Pneumonia

Ciprofloxacin vs Comparative Antibiotics in LRTI: A Meta-Analysis
Byf B, Kaufman L, Jacobs F, Derde MP, Thys JP

Diverse Clinical Studies

Oral and/or Intravenous Ciprofloxacin for Treatment of Multiply-Resistant Flavobacterium meningosepticum Septicaemia
Bolash NK, Liu HH

Safety and Efficacy of Parenteral Fleroxacin vs Ceftazidime in Mild to Moderate LRTI and SSTI and Complicated UTI
Shahabuddin S, Karnik A, Khan FA

Clinical Studies of Sparfloxacin in Surgical Infections
Yura J and the Japanese Collaborative Study Group of Sparfloxacin in Surgery

Once-Daily Administration of Lomefloxacin for Infections in Older Patients: A Summary of Worldwide Controlled Clinical Trials
McCue JD, Rizk E

Intravenous Pefloxacin vs Ceftriaxone in the Treatment of Nosocomial Infections
Presterl E, Graninger W, Fuegger R, Breyer S

Fluoroquinolones in the Treatment of Nursing Home Infections
McCue JD

Overview of Postmarketing Surveillance of Ofloxacin in Japan
Hanafusa T, Sawada M, Shimizu K, Maeda Y, Arauchi T, Kobayashi T, Okada S

Amoxicillin/Clavulanic Acid plus Ofloxacin in the Prevention of Infection in Head and Neck Surgery

Prevention of Nosocomial Infections in Cirrhotic Patients with Gastrointestinal Haemorrhage
Blaise M, Levacher S, Pateron D, Collignon A, Pourriat JL

Once-Daily Ofloxacin vs Twice-Daily Ciprofloxacin in the Treatment of Hospital Infections
Kitzes-Cohen R, Laor A, Raz R

Bone and Joint Infections

Comparative Penetration of 3 Fluoroquinolones into Human Cranial Bone Tissue after Administration of a Single Intravenous Dose
Pharmacokinetics of Intravenous Ofloxacin in Patients Undergoing Total Hip Endoprosthesis
Kapfer X, Hahn F, Dinkeldein U, Lucke C

Treatment of Chronic Reactive Arthritis with a 3-Month Course of Ciprofloxacin
Yli-Kerttula T, Luukkainen R, Merilahti-Palo R, Granfors K, Seppala J, Toivanen A

Ciprofloxacin in the Treatment of Chronic Osteomyelitis in Adults
Zavala Trujillo I, Valladares G, Nava A

Pefloxacin in the Treatment of Osteomyelitis
Gomis M, Barberán J, López-Arceo J, Pastor JM

Fluoroquinolones in the Management of Joint-Prosthesis Infection
Crémieux AC, Delage A, Oberlin C, Alnot JY, Carbon C

Pefloxacin after Failure of Initial Antibiotic Therapy in Children with Severe Invasive Salmonellosis
Gendrel D, Raymond J, Legall M-A, Bergeret M, Badoual J

Ciprofloxacin Use during Pregnancy
Bomford JAL, Ledger JC, O’Keeffe BJ, Reiter Ch

Comparison of Ciprofloxacin with Netilmicin in the Treatment of Acute Pyelonephritis: Reducing Hospital Stay
Bailey RR, Lynn KL, Robson RA, Peddie BA, Smith A

Shortened Hospital Stay with Sequential Intravenous/Oral Ciprofloxacin
Chrysanthopoulos CJ, Skoutelis AT, Bassaris HP

Economic Impact of IV and IV-to-PO Sequential Ciprofloxacin vs Standard IV Antibiotics
Paladino JA, Van Slooten A

Abbreviating the Duration of Intravenous Antibiotics with Oral Fluoroquinolones
Paladino JA, Cumbo TJ, Schentag JJ, Bloom MJ, Serrianne DJ, Burnett GJ

An Economic Assessment of Ofloxacin
Reinhart SP, Trotter JP

Sequential Therapy with Intravenous and Oral Ofloxacin in Severe ENT Infections
Kment G, Kornfehl J, Glatz H

Surgical Infections Treated Parenterally with Ofloxacin
Presterl E, Teleky B, Winkler S, Breyer S, Graninger W